Femasys Inc is trading at $4.29 (up 6.2%), staging a recovery after a sharp slide and a recent technical downgrade last week.
- The move appears to be a speculative bounce in a highly volatile micro-cap biotech stock rather than a news-driven rally.
- There have been no fresh company announcements, earnings reports, FDA decisions, or major analyst calls released so far on June 22, 2026.